Sphera Funds Management LTD. acquired a new stake in Aquestive Therapeutics Inc (NASDAQ:AQST) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 95,300 shares of the company’s stock, valued at approximately $1,669,000. Sphera Funds Management LTD. owned 0.38% of Aquestive Therapeutics as of its most recent SEC filing.
Other institutional investors have also recently made changes to their positions in the company. Keybank National Association OH acquired a new stake in shares of Aquestive Therapeutics in the third quarter valued at $239,000. Citadel Advisors LLC acquired a new stake in shares of Aquestive Therapeutics in the third quarter valued at $451,000. Engineers Gate Manager LP acquired a new stake in shares of Aquestive Therapeutics in the third quarter valued at $464,000. Brant Point Investment Management LLC acquired a new stake in shares of Aquestive Therapeutics in the third quarter valued at $622,000. Finally, Dean Capital Investments Management LLC acquired a new stake in shares of Aquestive Therapeutics in the third quarter valued at $655,000. Institutional investors and hedge funds own 64.49% of the company’s stock.
In related news, CEO Keith J. Kendall bought 7,950 shares of Aquestive Therapeutics stock in a transaction dated Friday, November 23rd. The stock was acquired at an average cost of $10.10 per share, with a total value of $80,295.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO John T. Maxwell bought 10,000 shares of Aquestive Therapeutics stock in a transaction dated Wednesday, November 21st. The shares were bought at an average cost of $9.80 per share, with a total value of $98,000.00. The disclosure for this purchase can be found here. Over the last ninety days, insiders have bought 25,650 shares of company stock valued at $249,931.
AQST has been the subject of several research analyst reports. Royal Bank of Canada set a $24.00 price objective on Aquestive Therapeutics and gave the company a “buy” rating in a report on Wednesday, November 7th. Wedbush set a $34.00 price objective on Aquestive Therapeutics and gave the company a “buy” rating in a report on Thursday, October 25th. JMP Securities initiated coverage on Aquestive Therapeutics in a report on Monday, August 20th. They issued an “outperform” rating and a $29.00 price objective for the company. BMO Capital Markets initiated coverage on Aquestive Therapeutics in a report on Monday, August 20th. They issued an “outperform” rating for the company. Finally, Zacks Investment Research lowered Aquestive Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. Aquestive Therapeutics has a consensus rating of “Buy” and an average price target of $27.67.
Shares of NASDAQ AQST opened at $8.25 on Friday. Aquestive Therapeutics Inc has a 12 month low of $7.47 and a 12 month high of $20.70. The company has a debt-to-equity ratio of 1.88, a quick ratio of 3.42 and a current ratio of 3.63.
Aquestive Therapeutics (NASDAQ:AQST) last announced its earnings results on Tuesday, November 6th. The company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.15). The firm had revenue of $13.27 million during the quarter, compared to analyst estimates of $14.75 million. As a group, research analysts expect that Aquestive Therapeutics Inc will post -1 EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “Sphera Funds Management LTD. Invests $1.67 Million in Aquestive Therapeutics Inc (AQST)” was originally published by American Banking News and is owned by of American Banking News. If you are viewing this story on another site, it was stolen and reposted in violation of US and international copyright & trademark law. The legal version of this story can be accessed at https://www.americanbankingnews.com/2018/12/08/sphera-funds-management-ltd-invests-1-67-million-in-aquestive-therapeutics-inc-aqst.html.
About Aquestive Therapeutics
Aquestive Therapeutics, Inc, a specialty pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs. Its products are developed using its PharmFilm technology. The company's marketed products include Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron antagonist for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery.
Featured Article: Return on Investment (ROI) Defined, Explained
Receive News & Ratings for Aquestive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquestive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.